DNAtrix is a clinical stage biotechnology company based in Houston, TX, specializing in the development of virus-driven immunotherapies for cancer. Their lead product, DNX-2401, is a genetically modified oncolytic virus designed to treat recurrent glioblastoma, a highly aggressive form of brain cancer.
With a focus on maximizing safety and efficacy, DNAtrix is developing a pipeline of novel viral-driven immunotherapies to combat various aggressive cancers. Their innovative approach involves using genetically modified viruses armed with potent immunomodulatory molecules, offering promising prospects for cancer treatment.
Generated from the website